Basic Information
| LncRNA/CircRNA Name | LINC00857 |
| Synonyms | NA |
| Region | GRCh38_10:80207710-80219657 |
| Ensemble | ENSG00000237523 |
| Refseq | NR_038464 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR |
| Sample | bladder cancer cell lines (UM-UC-3 and T24) |
| Expression Pattern | up-regulated |
| Function Description | Expression of the lncRNA, LINC00857, was found to be upregulated in tumors from patients that did not respond to platinum-based chemotherapy. Moreover, high expression of LINC00857 is correlated with shorter recurrence-free and overall survival of patients with MIBC. Knockdown of LINC00857 significantly decreased cell viability of bladder cancer cell lines through the induction of apoptosis. Furthermore, LINC00857 knockdown sensitized UM-UC-3 and T24 bladder cancer cells to cisplatin, via the negative regulation of the LMAN1 gene. |
| Pubmed ID | 29856124 |
| Year | 2018 |
| Title | LINC00857 Expression Predicts and Mediates the Response to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer |
External Links
| Links for LINC00857 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |